Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study
Lieske H Schrijver
(1)
,
Håkan Olsson
(2)
,
Kelly-Anne Phillips
(2, 3)
,
Mary Beth Terry
(4)
,
David E Goldgar
(5)
,
Karin Kast
(6)
,
Christoph Engel
(7, 8)
,
Thea M Mooij
(1)
,
Julian Adlard
(9)
,
Daniel Barrowdale
(10)
,
Rosemarie Davidson
(11)
,
Ros Eeles
(12)
,
Steve Ellis
(10)
,
D Gareth Evans
(13)
,
Debra Frost
(10)
,
Louise Izatt
(14)
,
Mary E Porteous
(15)
,
Lucy E Side
(16)
,
Lisa Walker
(17)
,
Pascaline Berthet
(18)
,
Valérie Bonadona
(19)
,
Dominique Leroux
(20, 21)
,
Emmanuelle Mouret-Fourme
(22)
,
Laurence Venat-Bouvet
(23)
,
Saundra S Buys
(24)
,
Melissa C Southey
(25)
,
Esther M John
(26, 27)
,
Wendy K Chung
(28)
,
Mary B Daly
(29)
,
Anita Bane
(30, 31)
,
Christi J van Asperen
(32)
,
Encarna B Gómez Garcia
(33)
,
Marian J E Mourits
(34)
,
Theo a M van Os
(35)
,
Marie-José Roos-Blom
(1)
,
Michael L Friedlander
(36, 37)
,
Sue-Anne Mclachlan
(3, 38)
,
Christian F Singer
(39)
,
Yen y Tan
(39)
,
Lenka Foretova
(40)
,
Marie Navratilova
(40, 41)
,
Anne-Marie Gerdes
(42)
,
Trinidad Caldes
(43)
,
Jacques Simard
(44)
,
Edith Olah
(45)
,
Anna Jakubowska
(46)
,
Brita Arver
(31)
,
Ana Osorio
(47)
,
Catherine Noguès
(48)
,
Nadine Andrieu
(49)
,
Douglas F Easton
(10)
,
Flora E van Leeuwen
(1)
,
John L Hopper
(3)
,
Roger L Milne
(3, 50)
,
Antonis C Antoniou
(10)
,
Matti A Rookus
(1)
1
NKI -
Netherlands Cancer Institute
2 Skane University Hospital [Lund]
3 University of Melbourne
4 Columbia Mailman School of Public Health
5 School of Medicine [University of Utah, Salt Lake City]
6 TU Dresden - Technische Universität Dresden = Dresden University of Technology
7 Department of Clinical Sciences [Lund]
8 Leipzig University / Universität Leipzig
9 Chapel Allerton Hospital
10 CAM - University of Cambridge [UK]
11 Queen Elizabeth University Hospital (Glasgow)
12 Royal Marsden NHS Foundation Trust
13 University of Manchester [Manchester]
14 Guy's and St Thomas NHS Foundation Trust [London]
15 Western General Hospital [Edinburgh, UK]
16 GOSHC - Great Ormond Street Hospital for Children NHS Foundation Trust [London, UK]
17 Churchill Hospital [Breast Care Unit]
18 UNICANCER/CRLC - Centre Régional de Lutte contre le Cancer François Baclesse [Caen]
19 UCBL - Université Claude Bernard Lyon 1
20 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
21 hôpital couple-enfant [CHU Grenoble Alpes]
22 Hôpital René Huguenin [Saint-Cloud]
23 Hôpital Dupuytren [CHU Limoges]
24 Huntsman Cancer Institute [Salt Lake City]
25 Monash University [Melbourne]
26 Stanford University
27 California Sciences Institute
28 Columbia University [New York]
29 Fox Chase Cancer Center
30 McMaster University [Hamilton, Ontario]
31 Karolinska Institutet [Stockholm]
32 LUMC - Leiden University Medical Center
33 GROW - School for Oncology and Developmental Biology [Maastricht]
34 UMCG - University Medical Center Groningen [Groningen]
35 AMC - Academic Medical Center - Academisch Medisch Centrum [Amsterdam]
36 UNSW - University of New South Wales [Sydney]
37 Prince of Wales Hospital
38 St. Vincent's Hospital, Sydney
39 Medizinische Universität Wien = Medical University of Vienna
40 MMCI - Masaryk Memorial Cancer Institute
41 University Hospital of Cologne [Cologne]
42 Copenhagen University Hospital
43 IdISSC - Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain]
44 ULaval - Université Laval [Québec]
45 National Institute of Oncology [Budapest, Hungary]
46 PUM - Pomeranian Medical University [Szczecin]
47 Spanish National Cancer Centre
48 SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
49 Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe
50 Cancer Epidemiology Centre & Cancer Council Victoria [Melbourne, Australia]
2 Skane University Hospital [Lund]
3 University of Melbourne
4 Columbia Mailman School of Public Health
5 School of Medicine [University of Utah, Salt Lake City]
6 TU Dresden - Technische Universität Dresden = Dresden University of Technology
7 Department of Clinical Sciences [Lund]
8 Leipzig University / Universität Leipzig
9 Chapel Allerton Hospital
10 CAM - University of Cambridge [UK]
11 Queen Elizabeth University Hospital (Glasgow)
12 Royal Marsden NHS Foundation Trust
13 University of Manchester [Manchester]
14 Guy's and St Thomas NHS Foundation Trust [London]
15 Western General Hospital [Edinburgh, UK]
16 GOSHC - Great Ormond Street Hospital for Children NHS Foundation Trust [London, UK]
17 Churchill Hospital [Breast Care Unit]
18 UNICANCER/CRLC - Centre Régional de Lutte contre le Cancer François Baclesse [Caen]
19 UCBL - Université Claude Bernard Lyon 1
20 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
21 hôpital couple-enfant [CHU Grenoble Alpes]
22 Hôpital René Huguenin [Saint-Cloud]
23 Hôpital Dupuytren [CHU Limoges]
24 Huntsman Cancer Institute [Salt Lake City]
25 Monash University [Melbourne]
26 Stanford University
27 California Sciences Institute
28 Columbia University [New York]
29 Fox Chase Cancer Center
30 McMaster University [Hamilton, Ontario]
31 Karolinska Institutet [Stockholm]
32 LUMC - Leiden University Medical Center
33 GROW - School for Oncology and Developmental Biology [Maastricht]
34 UMCG - University Medical Center Groningen [Groningen]
35 AMC - Academic Medical Center - Academisch Medisch Centrum [Amsterdam]
36 UNSW - University of New South Wales [Sydney]
37 Prince of Wales Hospital
38 St. Vincent's Hospital, Sydney
39 Medizinische Universität Wien = Medical University of Vienna
40 MMCI - Masaryk Memorial Cancer Institute
41 University Hospital of Cologne [Cologne]
42 Copenhagen University Hospital
43 IdISSC - Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain]
44 ULaval - Université Laval [Québec]
45 National Institute of Oncology [Budapest, Hungary]
46 PUM - Pomeranian Medical University [Szczecin]
47 Spanish National Cancer Centre
48 SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
49 Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe
50 Cancer Epidemiology Centre & Cancer Council Victoria [Melbourne, Australia]
Daniel Barrowdale
- Fonction : Auteur
- PersonId : 768869
- ORCID : 0000-0003-1661-3939
Jacques Simard
- Fonction : Auteur
- PersonId : 757778
- ORCID : 0000-0001-6906-3390
Anna Jakubowska
- Fonction : Auteur
- PersonId : 762556
- ORCID : 0000-0002-5650-0501
Catherine Noguès
- Fonction : Auteur
- PersonId : 21280
- IdHAL : catherine-nogues
- ORCID : 0000-0002-5768-6299
- IdRef : 030671175
Résumé
Background: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear.
Methods: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-cohort retrospective analyses were performed.
Results: For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by 26% (95% CI = 6% to 51%) and 39% (95% CI = 23% to 58%), respectively. For BRCA2 mutation carriers, OCP use was associated with BC risk in prospective analyses (HR = 1.75, 95% CI = 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated: HR = 1.06, 95% CI = 0.85 to 1.33; full cohort: HR = 1.52, 95% CI = 1.28 to 1.81). There was evidence of increasing risk with duration of use, especially before the first full-term pregnancy (BRCA1: both retrospective analyses, P < .001 and P = .001, respectively; BRCA2: full retrospective analysis, P = .002).
Conclusions: Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1 mutation carriers in young middle-aged women (40-50 years). For BRCA2 mutation carriers, a causal association is also not likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain safety of long-term OCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and nonhormonal contraceptive methods should be discussed.
Domaines
Sciences du Vivant [q-bio]| Origine | Publication financée par une institution |
|---|